Sagittarius Life Science

Sagittarius Life Science Current Assets

The Current Assets of Sagittarius Life Science (3205.TWO) as of Nov 3, 2026 is 12.14 M TWD. In the previous year, Current Assets was 89.92 M TWD — a change of -86.50% (lower).

Current Assets

12.14 MTWD

YoY

-86.50%

Last updated:

Current Assets of Sagittarius Life Science is 2025 12.14 M TWD. Current Assets of Sagittarius Life Science was 2024 89.92 M TWD. It decreases by -86.50% lower compared to the previous year.

The Sagittarius Life Science Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
55.69 M TWD
Jan 1, 2019
72.65 M TWD
Jan 1, 2020
502.82 M TWD
Jan 1, 2021
449.84 M TWD
Jan 1, 2022
351.05 M TWD
Jan 1, 2023
309.31 M TWD
Jan 1, 2024
89.92 M TWD
Jan 1, 2025
12.14 M TWD
The Sagittarius Life Science Current Assets history
YEARCurrent AssetsYoY
12.14 MTWD-86.50%
89.92 MTWD-70.93%
309.31 MTWD-11.89%
351.05 MTWD-21.96%
449.84 MTWD-10.54%
502.82 MTWD+592.13%
72.65 MTWD+30.44%
55.69 MTWD-21.14%
70.62 MTWD-77.26%
310.62 MTWD-43.50%
549.73 MTWD+67.14%
328.90 MTWD+45.26%
226.43 MTWD+0.29%
225.78 MTWD+14.48%
197.23 MTWD+83.83%
107.29 MTWD+13.86%
94.23 MTWD+39.56%
67.52 MTWD-44.49%
121.63 MTWD+39.47%
87.21 MTWD-18.31%
106.75 MTWD+25.37%
85.15 MTWD+95.88%
43.47 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sagittarius Life Science Stock analysis

What does Sagittarius Life Science do? Sagittarius Life Science Corp. generates revenue through the manufacture and sale of Chinese and western medicine, including nutrition and health formulations, natural and organic food, beverages, probiotic fermentation products, beauty care ingredients, Chinese herbal medicines, plant new medicines, and health supplies. The company serves domestic markets in Taiwan and overseas markets in Asia and the Americas, distributing its products through established channels. Technical services for pharmaceutical R&D are also a key revenue stream, supporting clients in developing both traditional and modern medicine solutions. The firm's product portfolio targets health-conscious consumers seeking natural and organic solutions, as well as businesses in the pharmaceutical and beauty care industries requiring specialized ingredients and formulations. Domestic sales focus on Taiwan, while international distribution extends to Asian regions outside of Taiwan and the Americas, reflecting a strategic market expansion. Revenue is derived from direct product sales and technical service contracts, with no mention of third-party partnerships or additional revenue streams beyond the described offerings. Sagittarius Life Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sagittarius Life Science stock

Current Assets of Sagittarius Life Science is 12.14 M TWD in 2025.

Current Assets of Sagittarius Life Science changed from 89.92 M TWD to 12.14 M TWD, representing a -86.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Sagittarius Life Science since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Sagittarius Life Science historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Sagittarius Life Science

All Key Metrics — Sagittarius Life Science